Search research articles
Contact Us
Filters
Showing results (81-90 of 118) with videos related to
Page
of 12
Sort By:
Archives of Dermatological Research
|
June 11, 2013
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study
A Nast, U Mrowietz, K Kragballe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
A Menter, R B Warren, R G Langley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 17, 2022
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis
M Gooderham, A Pinter, L K Ferris, et al.
The British Journal of Dermatology
|
July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
K B Gordon, R B Warren, A B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 22, 2018
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus
U Mrowietz, J Barker, W-H Boehncke, et al.
The British Journal of Dermatology
|
April 12, 2019
Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways
K Reich, J L K Reich, T M Falk, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 7, 2018
Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey
A Armstrong, S Jarvis, W-H Boehncke, et al.
The British Journal of Dermatology
|
June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
A Blauvelt, C Paul, P van de Kerkhof, et al.
The British Journal of Dermatology
|
November 16, 2018
Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
Z Z N Yiu, C Sorbe, M Lunt, et al.
The British Journal of Dermatology
|
October 20, 2019
Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)
R B Warren, J N W B Barker, A Y Finlay, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 118) with videos related to
Sort By:
Page
of 12
Archives of Dermatological Research
|
June 11, 2013
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study
A Nast, U Mrowietz, K Kragballe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
A Menter, R B Warren, R G Langley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 17, 2022
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis
M Gooderham, A Pinter, L K Ferris, et al.
The British Journal of Dermatology
|
July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
K B Gordon, R B Warren, A B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 22, 2018
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus
U Mrowietz, J Barker, W-H Boehncke, et al.
The British Journal of Dermatology
|
April 12, 2019
Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways
K Reich, J L K Reich, T M Falk, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 7, 2018
Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey
A Armstrong, S Jarvis, W-H Boehncke, et al.
The British Journal of Dermatology
|
June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
A Blauvelt, C Paul, P van de Kerkhof, et al.
The British Journal of Dermatology
|
November 16, 2018
Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
Z Z N Yiu, C Sorbe, M Lunt, et al.
The British Journal of Dermatology
|
October 20, 2019
Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)
R B Warren, J N W B Barker, A Y Finlay, et al.
Page
of 12